Zoledronic acid is a drug used to treat patients with hypercalcemia (high blood levels of calcium) caused by cancer. It is also used together with other drugs to treat multiple myeloma and to prevent bone fractures and reduce bone pain in people who have cancer that has spread to the bone. It is a type of bisphosphonate. Also called zoledronate and Zometa.
Researchers at the Osteoporosis and Metabolic Bone Disease Center and the Division of Gastroenterology at Loyola University Health System are studying a once-yearly, 15-minute infusion of an intravenous (IV) medication in patients with osteopenia (low bone mass) and inflammatory bowel diseases (IBD) that, if proven effective, may be considered the standard of treatment.
Results of a major trial of hormone therapy on men with locally advanced prostate cancer announced today were a significant development and would be welcomed by patients and oncologists world-wide, according to The Cancer Council Australia.
Data presented at the American Society of Clinical Oncology (ASCO) annual meeting in Orlando, Florida, demonstrate that Zometa (zoledronic acid), an intravenous bisphosphonate, was shown to inhibit bone loss in postmenopausal women treated with Femara (letrozole) in the adjuvant breast cancer setting (directly following surgery to prevent cancer recurrence).
Doctors at Long Island Jewish (LIJ) Medical Center recently discovered a link between a common chemotherapy drug and a serious bone disease called osteonecrosis of the jaw (ONJ).
One 15-minute infusion of the intravenous bisphosphonate zolendronic acid more rapidly reduced the biochemical markers of bone turnover in patients with Paget's disease than was seen in a head-to-head comparison with the oral treatment risedronate (95% vs. 75% response rate).